This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-15. Anything still debated is marked as such rather than presented as settled.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
Under Appendix I of CITES (the Convention on International Trade in Endangered Species), commercial international trade of Komodo dragon skins or specimens is prohibited. Despite this, there are occasional reports of illegal attempts to trade in live Komodo dragons. The most recent attempt was in March 2019, when Indonesian police in the East Java city of Surabaya reported that a criminal network had been caught trying to smuggle 41 young Komodo dragons out of Indonesia. The plan was said to include shipping the animals to several other countries in Southeast Asia through Singapore. It was hoped that the animals could be sold for up to 500 million rupiah (around US$35,000) each. It was believed that the Komodo dragons had been smuggled out of East Nusa Tenggara province through the port at Ende in central Flores. In 2013, the total population of Komodo dragons in the wild was assessed as 3,222 individuals, declining to 3,092 in 2014 and 3,014 in 2015. Populations remained relatively stable on the bigger islands (Komodo and Rinca), but decreased on smaller islands, such as Nusa Kode and Gili Motang, likely due to diminishing prey availability. On Padar, a former population of Komodo dragons has recently become extirpated, of which the last individuals were seen in 1975. It is widely assumed that the Komodo dragon died out on Padar following a major decline of populations of large ungulate prey, for which poaching was most likely responsible.
Many traditional markets in Taiwan originated as groups of peddlers and roadside stalls that organized into informal physical structures. By 2020, these markets had been in decline throughout Taiwan for decades and revitalization efforts have been largely unsuccessful. In 1997, a report by the Taipei city government indicated that the city had 61 major traditional markets with almost 10,000 registered vendors. The report also indicated that most of the city's markets were in serious need of repair and that almost 3,500 of the vendor stalls lay vacant. The Nanmen Market in Taipei is a government-owned traditional market that was opened in 1907 during the Japanese colonial rule. The market building was demolished in October 2019 and the market temporarily relocated until its replacement modern 12-floor building is completed in 2022.
=== Processing issues and solutions === Nanocapsules tend to aggregate and become unstable. Thus, substances within capsules can leak. To control the instability, nanocapsules can be dried either through spray drying or freeze-drying (lyophilization). Spray drying – Solutions are sprayed into a drying medium. This method is more widely used in the food industry and used for encapsulation of many food products as flavors, minerals, colors, and vitamins. This method makes nanocapsules more stable, and increases shelf-life of foods. Freeze-drying – This process involves dehydration of materials that are heat-sensitive. Unlike spray drying, water is removed through the sublimation process without changing the structure or shape of the nanoparticles. Freeze-drying involves four states: freezing, primary drying, secondary drying, and storage. Because of the multiple stages involved, this method is considered to demand more energy and time.
Max Bergmann (12 February 1886 – 7 November 1944) was a Jewish-German biochemist. Together with Leonidas Zervas, the discoverer of the group, they were the first to use the carboxybenzyl protecting group for the synthesis of oligopeptides.
Sources: en.wikipedia.org
=== Diagnostics === As anti-angiogenic cancer therapies have achieved widespread use, there has been increased interest in non-invasive monitoring of angiogenesis. One of the most extensively examined targets of angiogenesis is integrin αVβ3. Radiolabeled peptides containing RGD show high affinity and selectivity for integrin αVβ3 and are being investigated as tools to monitor treatment response of tumors via PET imaging. These include 18F-Galacto-RGD, 18F-Fluciclatide-RGD, 18F-RGD-K5, 68Ga-NOTA-RGD, 68Ga-NOTA-PRGD2, 18F-Alfatide, 18F-Alfatide II, and 18F-FPPRGD2. In a meta-analysis of studies using PET/CT in patients with cancer, it was shown that this diagnostic method may be very useful for detecting malignancies and predicting short-term outcomes, although larger-scale studies are needed.
== Other uses == Seed Science and Technology, a journal about seed science published by the International Seed Testing Association SST (typeface) Swiss Solvency Test, a framework for the regulation of the insurance industry in Switzerland Serious Sam: Tormental, a video game by Gungrounds Sales and Services Tax, a type of tax in Malaysia
Hence, blood with high carbon dioxide levels is also lower in pH (more acidic). Hemoglobin can bind protons and carbon dioxide, which causes a conformational change in the protein and facilitates the release of oxygen. Protons bind at various places on the protein, while carbon dioxide binds at the α-amino group. Carbon dioxide binds to hemoglobin and forms carbaminohemoglobin. This decrease in hemoglobin's affinity for oxygen by the binding of carbon dioxide and acid is known as the Bohr effect. The Bohr effect favors the T state rather than the R state. (shifts the O2-saturation curve to the right). Conversely, when the carbon dioxide levels in the blood decrease (i.e., in the lung capillaries), carbon dioxide and protons are released from hemoglobin, increasing the oxygen affinity of the protein. A reduction in the total binding capacity of hemoglobin to oxygen (i.e. shifting the curve down, not just to the right) due to reduced pH is called the root effect. This is seen in bony fish. It is necessary for hemoglobin to release the oxygen that it binds; if not, there is no point in binding it. The sigmoidal curve of hemoglobin makes it efficient in binding (taking up O2 in lungs), and efficient in unloading (unloading O2 in tissues). In people acclimated to high altitudes, the concentration of 2,3-Bisphosphoglycerate (2,3-BPG) in the blood is increased, which allows these individuals to deliver a larger amount of oxygen to tissues under conditions of lower oxygen tension.
== Occurrence == It is also produced by Cordyceps kyusyuensis (a close relative of C. militaris), but not by other insect pathogenic fungi such as C. bassiana, C. confragosa, C. takaomontana, Isaria fumosorosea, M. robertsii, and M. rileyi. Evidence for cordycepin in Ophiocordyceps sinensis (syn. Cordyceps sinensis) has been mixed, and its presence in this species was long considered controversial. More recent analyses using authenticated material and sensitive methods have detected low but measurable amounts: an HPLC–MS/MS study quantified cordycepin at 0.0076–0.029% (w/w) in authenticated wild material, a PLOS ONE comparison reported cordycepin in both cultivated and wild forms (higher on average in cultivated), and independent HPLC work found ~3 ppm in both wild and in‑vitro‑cultured O. sinensis mycelium. Overall, reported detection appears to be sample‑ and method‑dependent. It is also produced by Samsoniella hepiali (fungus identity confirmed by 18S rRNA) and Aspergillus nidulans Y176-2.
=== Agricultural biotechnology === RNAi has been used for a variety of agricultural applications including genetically engineered crops and insecticides. The use of the RNAi pathway has developed numerous products such as foods like Arctic apples, nicotine-free tobacco, decaffeinated coffee, nutrient fortified vegetation and hypoallergenic crops. The emerging use of RNAi has the potential to develop many other products for future use.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.